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Background/Aims: Whether alcohol intake increases the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis 
B virus (HBV) infection remains controversial. The aim of this study was to determine the effect of alcohol intake on the 
development of HCC. Methods: Between January 2006 and August 2008, 146 patients with an initial diagnosis of HCC who were 
hospitalized in 3 major hospitals in the Incheon area were enrolled as cases. Another 146 cirrhotic patients, who matched the 
cases by age and sex, were enrolled as controls. All cases and controls were HBsAg positive, and had a history of lifetime alcohol 
intake. Results: The cases and controls were aged 53±8 and 53±9 years (mean±SD), respectively, with each group comprising 
118 males and 28 females. The basal laboratory data, distribution of Child-Pugh class, HBeAg positivity (31.5% vs. 37.7%), HBV 
DNA level (5.74±2.35 vs. 5.98±2.29 log10 copies/mL), and proportion with a lifetime alcohol intake of more than 292 kg (30.8% vs. 
34.9%) did not differ between cases and controls. The cumulative alcohol intake and the proportion of heavy drinkers did not 
differ between the two groups in male patients. Conclusions: Alcohol intake might not increase the risk of HCC in patients with 
HBV infection. (Korean J Hepatol 2010;16:308-314)
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INTRODUCTION
Primary liver cancer is the fifth most common cancer and the 
third most common cause of cancer mortality in the world.
1 The 
proportion of hepatocellular carcinoma (HCC) is 85~90% in 
primary liver cancers.
2 Most of HCC cases occur in sub-Saharan 
Africa and Eastern Asia. The most common cause of HCC in 
these regions is hepatitis B virus (HBV).
2 
South Korea is located in Eastern Asia and has a high burden 
of HCC cases (male, 48.8/100,000; female, 11.6/100,000).
2 
Mortality of HCC is 22.7/100,000 (male, 34.1/100,000; female, 
11.2/100,000) and HCC is the most common cause of death in 
50~59 year old men.
3 Although prevalence of HBV infection is 
decreasing after the universal HBV vaccination, HBV is the most 
common cause of HCC in South Korea.
4 
The risk factors for HCC in patients with chronic HBV 
infection are older age, male gender, presence of cirrhosis, 
family history of HCC, co-infection with hepatitis C virus (HCV) 
or hepatitis D virus, presence of hepatitis B e antigen (HBeAg), 
high level of HBV DNA, and high dose of alcohol intake.
2 
However, most of these are also risk factors for the development 
of cirrhosis in patients with chronic HBV infection. Cirrhosis is 
one of the most important risk factors for HCC and is considered 
a premalignant condition.
5 In HBV-related HCC, 70~90% of 
cases have underlying cirrhosis.
2 Therefore, for investigating 
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patients with cirrhosis rather than patients with chronic hepatitis 
without cirrhosis. 
Alcohol plays an important role in the development of both 
cirrhosis
6 and HCC,
7,8 with a dose-effect relationship.
9 However, 
although heavy alcohol intake is associated with the develop-
ment of cirrhosis, there is still a controversy about a direct effect 
of alcohol on the development of HCC.
2 Synergism between 
alcohol intake and HCV infection for the development of HCC 
was demonstrated in several reports. Patients with chronic HCV 
infection and heavy alcohol intake have a 2- to 4-fold risk for 
HCC compared to non-alcoholic patients with HCV.
7,8,10 These 
findings revealed that there is a more than an additive interaction 
between alcohol and HCV infection. However, it is not clear 
whether alcohol intake adds to the risk of HCC in patients with 
chronic HBV infection.
This cross-sectional case-control study aimed to investigate 
whether heavy alcohol intake increase the incidence of HCC in 
patients with HBV-related cirrhosis.
PATIENTS AND METHODS
1. Patients
A total of 146 patients with an initial diagnosis of HCC, 
hospitalized in three major hospitals in the Incheon area, 
between January 2006 and August 2008, were enrolled as cases 
(HCC group). One hundred forty six cirrhotic patients, who 
matched the cases by age (±3 years) and sex, were enrolled as 
controls (cirrhosis group). Ethics Committees of each of the three 
hospitals approved this study, and written informed consents 
were obtained from all patients.
2. Diagnostic criteria of cirrhosis and HCC 
Criteria for enrollment of all cases and controls were presence 
of hepatitis B surface antigen (HBsAg, RIA, Abbott Laboratory, 
Chicago, IL, USA) and absence of anti-hepatitis C virus 
(anti-HCV, RIA, Abbott Laboratory, Chicago, IL, USA). Dia-
gnosis of cirrhosis was based on at least 2 of the following: 1) 
gastroesophageal varices on endoscopy, 2) cirrhotic surface or 
regenerating nodules of liver, and 3) splenomegaly by radiologic 
images (ultrasonography or computed tomography). Diagnosis 
of HCC was based on pathology or one of the following; 1) 
alpha-fetoprotein (AFP) ≥400 ng/mL and typical finding of 
HCC in radiologic image (abdominal computed tomography or 
abdominal magnetic resonance image or angiography), 2) AFP < 
400 ng/mL and typical finding of HCC in two kinds of radiologic 
images.
3 In the HCC group, 45 cases were confirmed by patho-
logy. All cases had underlying cirrhosis that was compatible to 
the above diagnostic criteria for cirrhosis.
3. Estimation of cumulative alcohol intake and 
laboratory data 
All cases and controls were interviewed at each hospital about 
their lifetime alcohol intake. Lifetime alcohol intake was 
estimated using mean alcohol intake per day, days of alcohol 
intake per week, and years of alcohol intake. The amount of 
lifetime alcohol intake was categorized according to estimated 
alcohol dose: <146, 146~291, 292~583, 584~875, and ≥876 kg. 
HBeAg (RIA, Shinjin Medics Inc., Goyang, Korea), HBV DNA 
level (real time PCR, Abbott, Wiesbaden, Germany), and other 
laboratory data were checked at initial diagnosis in the HCC 
group and at enrollment in the cirrhosis group. However, if 
antiviral agents were used, the HBeAg, HBV DNA level, and 
laboratory data prior to antiviral therapy were taken. A total of 28 
patients had oral antiviral treatment for median 17 (range:4-72) 
months. 
4. Statistical analysis
We assumed the difference between the proportion of 
exposure (alcohol intake) in cases and that in controls were 0.14 
(p1=0.26 in cases, p2=0.12 in controls) according to the result 
from Chen et al.
11 The minimum sample size was calculated as 
122 in each group, when alpha value was 0.05 and beta value was 
0.2. 
Continuous variables were expressed as the mean and 
standard deviation. The Student-t test was used for comparing 
continuous variables between the two groups. The Chi- square 
test was used for comparing categorical variables between the 
two groups. A P-value less than 0.05 was considered statistically 
significant. The SAS version 9.2 (SAS Institute Inc., Cary, NC, 
USA) was used for statistical analysis.
RESULTS
1. Clinical characteristics of the HCC and the 
cirrhosis groups 
The mean age was 53±8 years among cases and 53±9 years 
among controls. One hundred eighteen males and twenty eight 
females were enrolled for each pair of cases and controls. In the 310  The Korean Journal of Hepatology Vol. 16. No. 3, September 2010
Table 1. Clinical characteristics in the HCC and cirrhosis groups
HCC (n=146) Cirrhosis (n=146) p-value
Age (yr)
* 53±8 53 ±9 0.687
†
Male/Female 118/28 118/28 1.0
‡
AST (IU/L)
* 87±97 89 ±121 0.910
†
ALT (IU/L)
* 53±48 72 ±137 0.122
†
Albumin (g/dL)
* 3.4±0.7 3.4 ±0.7 0.383
†
Total bilirubin (mg/dL)
* 2.3±3.3 2.1 ±2.6 0.538
†
Platelet (×10
3/mm
3)
* 139±82 104 ±49 <0.001
†
Prothrombin time (sec)
* 14.8±2.9 15.0 ±2.9 0.515
†
AFP (ng/mL) 49.2 (1.06~332,800) 8.3 (0.01~706) 0.026
†
Child-Pugh class (A/B/C) 77/50/19 78/53/15 0.754
‡
HBeAg (+/-) 46/96 55/83 0.193
‡
HBV DNA (log10 copies/mL)
* 5.74±2.35 5.98 ±2.29 0.392
†
Four cases in HCC group and eight controls in cirrhosis group had no available HBeAg result. 
HCC, hepatocellular carcinoma; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; HBeAg, hepatitis 
B e antigen. 
*Data are shown as mean±SD except AFP [median(range)], 
†Student-t test, 
‡Chi-square test.
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Figure 1. Comparison of HBV DNA levels between the HCC and 
cirrhosis groups. The distribution of HBV DNA levels did not 
differ between the two groups. HBV DNA data were not available 
for four cases in the HCC group and nine controls in the cirrhosis 
group.
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Figure 2. Comparison of cumulative alcohol intake between the 
HCC and cirrhosis groups. The distribution of cumulative alcohol 
intake did not differ between the two groups. The proportion of 
heavy drinkers (lifetime alcohol intake greater than 292 kg) was 
30.8% (45/146) in the HCC group and 34.9% (51/146) in the 
cirrhosis group (p=0.455).
HCC group, number of patients belonging to HCC stage 
according to TNM staging system were the following: 34 in stage 
I, 54 in stage II, 38 in stage III, and 20 in stage IV. There were no 
differences in the levels of aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), albumin, total bilirubin, pro-
thrombin time, and the distribution of Child-Pugh class between 
the two groups. Platelet count was higher in the HCC group than 
in the cirrhosis group (139±82 vs. 104±49×10
3/mm
3, p<0.001). 
The level of AFP was higher in the HCC group than in the 
cirrhosis group [49.2 (1.06~332,800) vs. 8.3 (0.01~706) ng/mL, 
p=0.026] (Table 1).
2. HBeAg and HBV DNA levels of the HCC and 
the cirrhosis groups 
There were no differences in HBeAg positivity and mean 
HBV DNA level between the HCC and cirrhosis groups (Table 
1). The levels of HBV DNA were categorized as <3, 3~4.9, 
5~6.9, and ≥7 log10 copies/mL. There was no difference in the 
distribution of HBV DNA levels between the two groups (Fig. 1).
3. Amount of cumulative alcohol intake of the 
HCC and the cirrhosis groups 
There was no difference in the distribution of cumulative 
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Table 2. Clinical characteristics of male patients in the HCC and cirrhosis groups
HCC (n=118) Cirrhosis (n=118) p-value
Age (yr)
* 51±7 52±8 0.616
†
AST (IU/L)
*  92±102 93±130 0.950
†
ALT (IU/L)
* 57±51 80±151 0.124
†
Albumin (g/dL)
* 3.4±0.7 3.5±0.7 0.171
†
Total bilirubin (mg/dL)
* 2.4±3.5 2.0±2.6 0.415
†
Platelet (×10
3/mm
3)
* 141±79 107±50 <0.001
†
Prothrombin time (sec)
* 14.5±2.4 14.9±2.8 0.230
†
AFP (ng/mL) 52.54 (1.5~332,800) 7.6 (0.69~706) 0.030
†
Child-Pugh class (A/B/C) 63/39/16 67/40/11 0.587
‡
HBeAg (+/-) 39/75 45/66 0.326
‡
HBV DNA (log10 copies/mL)
*  5.75±2.34 5.99±2.24 0.436
†
Four cases in HCC group and seven controls in cirrhosis group had no available HBeAg result. 
HCC, hepatocellular carcinoma; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; HBeAg, hepatitis 
B e antigen .
*Data are shown as mean±SD except AFP [median (range)], 
†Student-t test, 
‡Chi-square test.
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Figure 3. Comparison of HBV DNA levels in male patients 
between the HCC and cirrhosis groups. The distribution of HBV 
DNA levels did not differ between the two groups. HBV DNA data 
were not available for three cases in the HCC group and nine 
controls in the cirrhosis group.
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Figure 4. Comparison of cumulative alcohol intake by male 
patients between the HCC and cirrhosis groups. The cumulative 
alcohol intake did not differ between the two groups. The 
proportion of heavy drinkers (lifetime alcohol intake greater than 
292 kg) was 38.1% (45/118) in the HCC group and 40.7% (48/118) 
in the cirrhosis group (p=0.689).
The proportion of heavy alcohol drinkers defined as alcohol 
intake over than 80 g/day and more than 10 years, was 30.8% 
(45/146) in the HCC group and 34.9% (51/146) in the cirrhosis 
group. There was no difference in the number of heavy alcohol 
drinkers between the two groups (p=0.455). 
4. Clinical characteristics of HCC and cirrhosis 
groups in male patients
One hundred eighteen male patients were enrolled for each 
pair of cases and controls. The mean age was 51±7 years among 
cases and 52±8 years among controls. There were no differences 
in the levels of AST, ALT, albumin, total bilirubin, prothrombin 
time, and the distribution of Child-Pugh class between the two 
groups. Platelet count was higher in the HCC group than in the 
cirrhosis group (141±79 vs. 107±50×10
3/mm
3, p<0.001). The 
level of AFP was higher in the HCC group than in the cirrhosis 
group [52.54 (1.5~332,800) vs. 7.6 (0.69~706) ng/mL, p=0.030] 
(Table 2).
5. HBeAg and HBV DNA levels between HCC and 
cirrhosis groups in male patients
There were no differences in HBeAg positivity and mean 
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The levels of HBV DNA were categorized as <3, 3~4.9, 5~6.9, 
and ≥7 log10 copies/mL. There was no difference in the distribu-
tion of HBV DNA levels between the two groups (Fig. 3).
6. Amount of cumulative alcohol intake between 
HCC and cirrhosis groups in male patients 
There was no difference in the distribution of cumulative 
alcohol intake between the HCC and cirrhosis groups (Fig. 4). 
The proportion of heavy alcohol drinkers was 38.1% (45/118) in 
HCC group and 40.7% (48/118) in cirrhosis group. There was no 
difference in the number of heavy alcohol drinkers between the 
two groups (p=0.689). 
DISCUSSION
Chronic alcohol intake induces a variety of liver diseases such 
as fatty liver, liver fibrosis, cirrhosis, and HCC. In addition, it 
may increase the rate of progression to cirrhosis and HCC in 
patients with chronic HBV infection. A synergism between 
alcohol intake and HBV infection on the development of HCC 
was reported in patients with chronic HBV infection.
7,12 
However, other reports showed that alcohol intake did not add to 
the risk of HCC in patients with chronic HBV infection.
13-15 
To minimize error in the estimation of cumulative alcohol 
intake, in this study, alcohol dose was categorized according to 
the amount of a heavy alcohol drink. The dose of a heavy alcohol 
drink was defined as 292 kg of ethanol or more than this amount. 
The 292 kg of ethanol is compatible to the amount of a daily 
intake of 80 g ethanol for 10 years. This amount of ethanol 
usually induces alcoholic liver diseases in man, although a less 
amount of ethanol than this induces alcoholic liver diseases in 
woman.
16 In this case-control study, the amount of past cumulative 
alcohol intake did not add to the risk of HCC in patients with 
HBV-related cirrhosis. 
Because women are more susceptible to alcohol than men, 
woman can easily develop alcohol-mediated hepatotoxicity and 
severe forms of alcoholic liver disease.
17 Therefore, a sub-group 
analysis including only men was done for determining alcohol 
effect on the development of HCC. The result of sub-group 
analysis also showed that alcohol intake did not add to the risk of 
HCC in male patients with HBV-related cirrhosis. 
All findings in this study showed that alcohol intake did not 
add to the risk of HCC in patients with HBV-related cirrhosis. 
Even a very high alcohol dose did not add to the risk of HCC. 
Many studies about alcohol effect on the development of HCC 
defined their own alcohol dose that possibly induces alcoholic 
liver disease. Therefore, it is very difficult to reach a conclusion 
about the effect of alcohol intake on the development of HCC. In 
addition, it is uncertain as to the amount of alcohol intake needed 
to induce advanced liver diseases or HCC. Some reported that an 
alcohol intake of more than 50-70 g/day is a risk factor for HCC.
2 
In patients with chronic HCV infection, alcohol intake of more 
than 60-80 g/day increased the risk of HCC from 2-4 times.
7,8,10 
However, it is unclear how much alcohol intake adds to the risk 
of HCC, and whether low or moderate alcohol intake also is a 
risk factor for HCC in patients with chronic HBV infection. In 
this study, the amount of alcohol intake was categorized to 
investigate the amount of alcohol needed to increase the risk of 
HCC. However, there was no difference in the distribution of 
cumulative alcohol intake between the HCC and cirrhosis 
groups. 
The risk of HCC is higher in former drinkers, who have ceased 
alcohol drinking for up to 10 years, than in those who continue to 
drink alcohol.
7,18 This paradoxical observation is explained by 
the fact that patients stop drinking due to the early signs of liver 
disease, but the underlying hepatic disease remains and 
influences the risk of HCC development. In contrast, patients 
who continue to intake alcohol in spite of signs of liver disease 
will often die from complications of alcoholic liver disease prior 
to the development of HCC.
18 In the aspect of patients with 
chronic HBV infection, continuous alcohol drinking may 
aggravate pre-existing liver disease and finally shorten the life 
expectancy prior to the occurrence of HCC. Because of this 
hypothesis, even though alcohol can add to the risk of HCC, 
there is no definite evidence of carcinogenic effect of alcohol in 
many studies, and controversies remain as to whether alcohol 
can add to the risk of HCC in patients with chronic HBV 
infection. 
The seropositivity of HBeAg is a risk factor not only for 
cirrhosis,
19,20 but also for HCC.
11,21 However, cirrhosis and HCC 
actually developed many years after HBeAg seroconversion,
22 
and an estimated 65% of liver complications occurred after 
HBeAg seroconversion.
23 Generally, absence of HBeAg means 
inactive carrier status if ALT levels are normal and HBV DNA 
levels are low. However, some patients without HBeAg show an 
active liver disease state and have high levels of ALT and HBV 
DNA. Therefore, it is difficult to interpret the association 
between HBeAg status and clinical outcomes without consi-
dering ALT and HBV DNA levels. In this study, the seroposi-
tivity of HBeAg was not a risk factor for HCC in patients with Oh Sang Kwon, et al. Alchohol and HCC in HBV-related cirrhosis  313
cirrhosis. Because HBeAg is a common risk factor for both HCC 
and cirrhosis, it could not remain as a risk factor for HCC in 
patients with underlying cirrhosis.  
A high level of HBV DNA is a risk factor not only for 
cirrhosis,
24 but also for HCC.
11,25 In addition, serum HBV DNA 
level at initial enrollment has a linear relationship with HCC risk; 
the higher the HBV DNA level, the more risk of HCC 
development.
11 However, due to the fluctuating level of HBV 
DNA during a lifetime, the accuracy of one high HBV DNA 
level at a single time point may not predict the risk of HCC 
development. For example, it is not understandable that all 
young HBV carriers who have a very high level of HBV DNA at 
one single point develop HCC in later their life. In this study, 
HBV DNA level was not associated with the development of 
HCC in patients with cirrhosis. Because high HBV DNA level is 
a common risk factor for both HCC and cirrhosis, it could not 
remain as a risk factor for HCC in patients with underlying 
cirrhosis. 
The role of HBV genotypes in the development of HCC is still 
controversial, because the prevalence of genotypes is variable 
according to geographic region. According to a U.S.A. study, 
although patients with HBV genotype C have an increased risk of 
HCC compared to patients with other genotypes, it was not 
statistically significant after accounting for other variables.
26 
However, studies from Taiwan showed a 3-to 6-fold increased 
risk of HCC in patients with HBV genotype C compared to 
patients with genotype B.
27,28 Because the prevalence of 
genotype C in Korea is over 99% in patients with chronic HBV 
infection,
29 this study did not evaluate the impact of HBV 
genotype on the development of HCC.
Cirrhosis has been presented as a strong risk factor for HCC in 
patients with chronic HBV infection. It was associated with a 
3.6-fold increased risk of developing HCC, in a U.S.A. study
26 
and nearly a 10-fold increased risk of HCC, even after accounting 
for other markers of disease severity such as elevated ALT or 
HBV DNA levels, in studies from Taiwan and China.
11,30 
Cirrhosis also has been presented as a strong risk factor for HCC 
in patients with alcoholic liver disease.
31 Because cirrhosis, 
independent of its cause (alcohol, HBV, HCV, etc), is associated 
with a high risk of HCC, some hepatologists think that the high 
rate of HCC in patients with chronic HBV infection may merely 
reflect the fact that HBV is a common cause of cirrhosis.
32 In 
addition, alcohol does not directly induce HCC, but just induces 
cirrhosis, which predisposes to the development of HCC.
5 
Therefore, because all cases and controls had cirrhosis, this study 
could not find a risk factor for HCC.  
In the present study, some limitations exist in evaluating the 
risk of HCC. First, in quantifying alcohol intake, most studies 
depend on interviews with patients or their families. However, 
this method may lead to an invalid estimate of alcohol intake due 
to many biases.
33 Although interviews for quantity of alcohol 
intake were performed by trained individuals, there remains 
uncertainty in quantifying lifetime alcohol intake. Second, 
diagnosis of cirrhosis was clinically determined by endoscopy 
and imaging studies. Although liver biopsy is the gold standard 
for diagnosis of cirrhosis, it is dangerous to patients with 
decompensated cirrhosis and not an ethical tool for the aim of 
this study. Third, if history of the amount of alcohol intake after 
the development of cirrhosis was taken for each pair of cases and 
controls, effect of alcohol on the development of HCC was more 
accurately determined. However, it was impossible to know 
when each case and control developed cirrhosis. Fourth, this 
study was designed as case-control study. Although cohort study 
has better statistic power than case-control study, it needs long 
term follow up for the observation of HCC occurrence. In 
addition, alcoholics frequently drop out of study protocol. 
Therefore, further study that has more powerful statistics and can 
track patients more thoroughly is needed. 
In conclusion, this case-control study showed there were no 
significant differences in cumulative alcohol intake, HBeAg 
positivity, and HBV DNA levels between the HCC and cirrhosis 
groups. Prospective cohort study is needed to clarify the risk 
factors for development of HCC in patients with HBV-related 
cirrhosis.
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